Bristol-Myers Squibb (NY:BMY)

These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?

December 19, 2024

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

December 18, 2024

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Via Investor's Business Daily

Is Bristol-Myers Squibb Stock a Millionaire Maker?

December 02, 2024

Where Will Bristol Myers Squibb Be in 5 Years?

November 24, 2024

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

From FN Media Group LLC

Via GlobeNewswire

Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation

December 17, 2024

HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties and pricing agreement termination.

Via Benzinga

Is Bristol Myers Squibb Stock a Buy?

November 21, 2024

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

December 17, 2024

Via Benzinga

Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook

December 16, 2024

Bristol-Myers Squibb Inc. (NYSE: BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to...

Via Benzinga

9 Health Care Stocks With Whale Alerts In Today's Session

December 16, 2024

Via Benzinga

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

December 16, 2024

Via Benzinga

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

Bristol Myers Squibb Announces Dividend Increase

December 11, 2024

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

December 09, 2024

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

December 03, 2024

Via Benzinga

Why Is Purple Biotech Stock Trading Higher On Monday?

December 02, 2024

Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes.

Via Benzinga

Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program

November 29, 2024

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Via Benzinga

Topics Lawsuit

3 Magnificent S&P 500 Dividend Stocks Down 27%, 28%, and 29% to Buy and Hold Forever

November 29, 2024

The sell-offs of these stocks were driven by issues that were never going to last.

Topics Stocks

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

November 26, 2024

AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like.

AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback

November 22, 2024

Via Investor's Business Daily

Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks

November 21, 2024

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

November 19, 2024

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases

November 18, 2024

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

Via Benzinga

Not-So-Big Pharma

November 16, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Via Talk Markets

Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16

November 16, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Nov. 11-15, 2024.

Via Talk Markets

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue

November 15, 2024

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments.

Via Benzinga

Topics Lawsuit

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

November 15, 2024

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

November 15, 2024